Intelligence · Clinical Pipeline

George Institute for Pipeline

All ClinicalTrials.gov programs at George Institute for — phase, modality, and trial IDs.

Programs
406

Quick answer

George Institute for has 406 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. RIBOCICLIB, Kisqali 200 mg film-coated tablets

    The George Institute

    Hormone receptor–positive (HRpos)/human epidermal growth factor receptor 2–negative (HER2neg) early breast cancer at risk of recurrence

    approved small molecule active

    1 trial
  2. ROSUVASTATIN AND EZETIMIBE , BEMPEDOIC ACID , ROSUVASTATIN AND EZETIMIBE , ATORVASTATIN AND AMLODIPINE

    The George Institute

    CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arthritis or psoriatic arthritis or axial spondyloarthritis or systemic lupus erythematosus

    approved small molecule active

    1 trial
  3. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze Tollwut-Impfstoff (inaktiviert), RABIPUR, poudre et solvant pour solution injectable en seringue préremplie. Vaccin rabique (inactivé)., Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    rabies pre-exposure prophylaxis

    approved small molecule active

    1 trial
  4. Rapamune 1 mg coated tablets, MYCOPHENOLATE MOFETIL

    The George Institute

    End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA

    approved small molecule active

    1 trial
  5. Recigarum 1,5 mg comprimidos recubiertos con película EFG

    The George Institute

    Active smokers

    approved small molecule active

    1 trial
  6. Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE

    The George Institute

    Latent tuberculosis infection in patients with end-stage kidney disease.

    approved small molecule active

    1 trial
  7. Ropivacaine B. Braun 10 mg/ml injektionsvätska, lösning

    The George Institute

    lumbar arthrodesis

    approved small molecule active

    1 trial
  8. SILDENAFIL , LEVOTHYROXINE SODIUM

    The George Institute

    erectile function, hypothyroidism subclinic

    approved small molecule active

    1 trial
  9. SINECATECHINS

    The George Institute

    Anal high-grade squamous intraepithelial lesions (HSIL).

    approved small molecule active

    1 trial
  10. SUMATRIPTAN , GLYCERYL TRINITRATE , RIMEGEPANT

    The George Institute

    Migraine

    approved small molecule active

    1 trial
  11. Sitagliptin 50mg Film-coated Tablets, Trajenta 5 mg film-coated tablets, Pioglitazone Mylan 15 mg compresse, Ozempic 0.5 mg solution for injection in pre-filled pen, Jardiance 10 mg film-coated tablets, GLUCOPHAGE 1000 mg potahované tablety, Invokana 100 mg film-coated tablets, Trulicity 1.5 mg solution for injection in pre-filled pen, Galvus 50 mg tablets, Forxiga 10 mg film-coated tablets

    The George Institute

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial
  12. Sulfato de Magnesio Altan 150 mg/ml solución inyectable y para perfusión EFG, LIDOCAINE HYDROCHLORIDE, Dexdor 100 micrograms/ml concentrate for solution for infusion, KETOLAR 50 mg/ml solución inyectable.

    The George Institute

    Obesity

    approved small molecule active

    1 trial
  13. TACROLIMUS, SIROLIMUS, MYCOPHENOLATE MOFETIL, AZATHIOPRINE, PREDNISOLONE, EVEROLIMUS, MYCOPHENOLIC ACID, BELATACEPT, CICLOSPORIN

    The George Institute

    BK Polyomavirus DNAemia after kidney transplantation

    approved small molecule active

    1 trial
  14. TESTOGEL 50 mg gel transdérmico en sobres, Decapeptyl diario 0,1 mg polvo y disolvente para solución inyectable, Bemfola 300 IU/0.50 mL solution for injection in pre-filled pen, Astarté 0,25 mg/0,5 ml solución inyectable en jeringa precargada EFG

    The George Institute

    low ovarian reserve according to Bologna criteria and carriers of androgen receptor polymorphism

    approved small molecule active

    1 trial
  15. TRANEXAMIC ACID

    The George Institute

    Hip fracture

    approved small molecule active

    1 trial
  16. Trangorex 200 mg comprimidos

    The George Institute

    Atrial fibrillation

    approved small molecule active

    1 trial
  17. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    The George Institute

    IgA nephropathy

    approved small molecule active

    1 trial
  18. Urapidil Accord 5 mg/ml solución inyectable y para perfusión EFG, Trandate 5mg/ml Solution for Injection, Fenilefrina Altan 0,1 mg/ml solución inyectable y para perfusión.

    The George Institute

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  19. Vabysmo 120 mg/mL solution for injection in pre-filled syringe

    The George Institute

    SUBRETINAL HYPERREFLECTIVE MATERIAL

    approved small molecule active

    1 trial
  20. Vyvgart 20 mg/mL concentrate for solution for infusion

    The George Institute

    Patients affected by generalized myasthenia gravis

    approved small molecule active

    1 trial
  21. Wegovy 2.4 mg solution for injection in pre-filled pen

    The George Institute

    obstructive sleep apnea

    approved small molecule active

    1 trial
  22. Xtandi - 40 mg soft capsules

    The George Institute

    PROSTATE CANCER

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does George Institute for have?

406 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs